GLP-2 analogues (teduglutide and apraglutide) induced lasting intestinal length growth in neonatal short-bowel piglets that persisted or increased after treatment cessation, unlike mucosal changes that faded.
Growth persists after stoppingIntestinal length growth from GLP-2 treatment was maintained or increased 7 days after stopping treatment (p<0.001) — suggesting lasting structural change, not temporary stimulation
What the researchers found
GLP-2 analogues increased intestinal length by day 7 (p=0.005), maintained (teduglutide) or further increased (apraglutide) at day 14 after cessation (p<0.001). Mucosal adaptation (villus hyperplasia) was not durable after treatment cessation.
Why it matters
Lasting intestinal growth means GLP-2 treatment courses could permanently improve gut capacity in infants with short bowel syndrome, potentially freeing them from lifelong IV nutrition — a transformative outcome.
The numbers in context
P=0.005 length at day 7; P<0.001 at day 14; villus hyperplasia P=0.081 at day 14; teduglutide 0.05mg/kg BID; apraglutide 5mg/kg twice weekly
How the study worked
Neonatal short-bowel piglet model. Three groups: saline control, teduglutide (0.05mg/kg twice daily × 7 days), apraglutide (5mg/kg twice weekly × 7 days). Endpoints at day 7 and day 14 (7 days after cessation). Intestinal length, weight, histology, and mucosal gene expression measured.
Who was studied
Neonatal piglets with surgically created short bowel syndrome
What this study cannot tell us
Neonatal piglet model — human neonatal intestine may respond differently. Short observation period (14 days). Only two GLP-2 analogues tested. Molecular mechanisms of lasting growth not identified. Long-term outcomes and functional absorption capacity not assessed.
How to read the evidence
Moderate evidence: well-designed neonatal animal model with controlled comparison between two GLP-2 analogues, but limited to piglets and short follow-up.
When this study was published
Published 2021. Apraglutide and teduglutide continue in clinical development for short bowel syndrome.
The bigger picture
This distinguishes two types of intestinal response to GLP-2: temporary mucosal changes and lasting structural growth. For neonates, who have natural growth potential, GLP-2 drugs could catalyze permanent intestinal lengthening — potentially curative for short bowel syndrome.
Questions still open
- How long does the intestinal length growth persist beyond 14 days?
- Does longer-acting apraglutide produce greater permanent lengthening than teduglutide?
- Can GLP-2 treatment during a critical neonatal window cure short bowel syndrome?
Common questions
Can GLP-2 drugs grow more intestine?
What is the difference between teduglutide and apraglutide?
Read the original research
Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.
JPEN. Journal of parenteral and enteral nutrition, 45(7), 1466-1474
Citation
Hinchliffe, Tierah; Pauline, Mirielle L; Wizzard, Pamela R; Nation, Patrick N; Brubaker, Patricia; Campbell, Jhenielle R; Kim, Yunji; Dimitriadou, Violetta; Wales, Paul W; Turner, Justine M. (2021). Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.. JPEN. Journal of parenteral and enteral nutrition, 45(7), 1466-1474. https://doi.org/10.1002/jpen.2053